EMA Deciding If Donanemab For Alzheimer’s & Three Other Drugs Merit Fast-Tracking

Eli Lilly, MSD, CLS and Pfizer could this week find out if the European Medicines Agency will agree that their planned EU marketing applications for donanemab, sotatercept, garadacimab and aztreonam-avibactam respectively deserve an accelerated assessment.

Alzheimer's puzzle
Lilly's donanemab is designed to slow Alzheimer’s disease progression • Source: Shutterstock

More from Europe

More from Geography